Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.

ABSTRACT:

Background

CD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL). Here, we evaluated the antitumor activities of CD38/CD47 bispecific antibodies (BsAbs).

Methods

Five suitable anti-CD38 antibodies for co-targeting CD47 and CD38 BsAb were developed using a 2 + 2 "mAb-trap" platform. The activity characteristics of the CD38/CD47 BsAbs were evaluated using in vitro and in vivo systems.

Results

Using hybridoma screening technology, we obtained nine suitable anti-CD38 antibodies. All anti-CD38 antibodies bind to CD38⁺ tumor cells and kill tumor cells via antibody-dependent cellular cyto

SUBMITTER: Li S 

PROVIDER: S-EPMC11231100 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature